935-P: Favorable Shift in CGM Glucose in Youth with T1D during COVID-19 Pandemic

Abstract

Aim: COVID-19 caused disruption with potential for changes in lifestyle and T1D care behaviors, especially for youth. We compared CGM-derived glucometrics during the COVID-19 pandemic with the previous year in a clinic-based pediatric sample with T1D using CGM.Method: We used EHR-extracted data to compare CGM metrics during the pandemic (3/16/20 -10/29/20) with the same calendar months in 2019. The sample comprised youth using CGM, aged 1-18 years, with T1D duration ≥6 months (age <6 years) or ≥1 year (age ≥6 years).Results: The pre-pandemic sample comprised 578 youth (53% female, age 12.4±3.5, T1D 6.2±3.5 years). The pandemic sample comprised 605 youth (54% female, age 13.4±3.6, T1D 6.8±3.8 years). Over 80% of youth were common to both samples. Mean CGM glucose was 7 mg/dL lower during the pandemic (186±35) vs. pre-pandemic (193±33) (p<.001). The proportion of youth with mean glucose <145 and 145-154 mg/dL increased 80-100% during the pandemic (5 to 9% and 5 to 10%, respectively), while the proportion with mean glucose ≥210 mg/dL decreased by 29% (31 to 22%). The % of youth with glucose management indicator (GMI) <7% increased by >110% (Figure). The 7-12y age group showed the largest shift in GMI: 8.0 pre- vs. 7.7% during pandemic (p=.003).Conclusion: There was a beneficial shift in glucose levels from pre to during the pandemic. Future studies are needed to assess how changes in healthcare during the pandemic may have improved glycemic outcomes.View largeDownload slideView largeDownload slide DisclosureT. Kaushal: None. L. J. Tinsley: None. L. K. Volkening: None. L. Ambler-osborn: None. L. M. Laffel: Consultant; Self; AstraZeneca, Boehringer Ingelheim International GmbH, Dexcom, Inc., Dompe, Insulogic LLC, Janssen Pharmaceuticals, Inc., Laxmi Therapeutic Devices, LifeScan, Lilly Diabetes, Medtronic, Provention Bio, Inc.FundingNational Institutes of Health (K12DK094721, P30DK036836)